Recombinant allergen with reduced enzymatic activity

摘要

The present invention provides a novel treatment for allergy comprising the provision of a recombinant allergen with reduced enzymatic activity. Vaccines comprising said mutant allergens stimulate a Th1-type immune response in allergic or naive individuals, thereby reducing the potential for an allergic response upon contact with wild-type allergen. Preferably said allergen is DerP1.